Trial Section
Home / Trial Section / Clinical Trial| Indication | Department | Study Title | Study Phase | Investigator | Contact Person | Status |
|---|---|---|---|---|---|---|
| Solid Tumor | Colorectal Surgery | A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab(ABBV-151) as a Single Agent and in Combination with Budigalimab(ABBV-181) in Subjects with Locally Advanced or Metastatic Solid Tumors | Phase I | WANG,JAW-YUAN | 江婕綺 | On-going |
| Gastric Cancer | Colorectal Surgery | A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (Aspen-06) | Phase II | WANG,JAW-YUAN | On-going | |
| Gastric Cancer | Colorectal Surgery | nextHERIZON: AN OPEN-LABEL, SIGNAL GENERATING, PHASE 2 STUDY OF HER-VAXX IN COMBINATION WITH CHEMOTHERAPY OR PEMBROLIZUMAB IN PATIENTS WITH METASTATIC HER2/NEU OVER-EXPRESSING GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMAS WHO HAVE PREVIOUSLY RECEIVED TRASTUZUMAB AND PROGRESSED ON THIS TREATMENT | Phase II | WANG,JAW-YUAN | On-going | |
| Colorectal Cancer | Colorectal Surgery | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | Phase III | WANG,JAW-YUAN | 江婕綺 | On-going |
| Gastric Cancer | Colorectal Surgery | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) | Phase III | WANG,JAW-YUAN | 江婕綺 | On-going |
| Colorectal Surgery | A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression (FORTITUDE-101) | Phase III | WANG,JAW-YUAN | 江婕綺 | On-going | |
| Colorectal Cancer | Colorectal Surgery | A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation | Phase III | WANG,JAW-YUAN | 江婕綺 | On-going |
| Gastric Cancer | Colorectal Surgery | MOUNTAINEER-02: A randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC) | Phase II | WANG,JAW-YUAN | 崔雅潔 | Completed |
| Colorectal Cancer | Colorectal Surgery | A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy | Phase III | WANG,JAW-YUAN | 江婕綺 | On-going |
| Colorectal Cancer | Colorectal Surgery | An Open-label, Multicenter, Randomized Phase 3 Study of First-line Encorafenib Plus Cetuximab With or Without Chemotherapy versus Standard of Care Therapy with a Safety Lead-in of Encorafenib and Cetuximab Plus Chemotherapy In Participants with Metastatic BRAF V600E-Mutant Colorectal Cancer | Phase III | WANG,JAW-YUAN | 江婕綺 | On-going |
← Please slide to the left for more information